Daiwa Securities Group Inc. decreased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 71.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 26,500 shares of the company’s stock after selling 65,852 shares during the period. Daiwa Securities Group Inc.’s holdings in Teva Pharmaceutical Industries Limited were worth $466,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Capital Research Global Investors raised its position in shares of Teva Pharmaceutical Industries Limited by 13.8% during the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after buying an additional 9,260,426 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Teva Pharmaceutical Industries Limited by 11.1% during the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after buying an additional 6,685,844 shares during the last quarter. FMR LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 16.7% during the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after buying an additional 6,115,853 shares during the last quarter. Capital World Investors raised its position in shares of Teva Pharmaceutical Industries Limited by 41.9% during the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after buying an additional 3,268,200 shares during the last quarter. Finally, Alliancebernstein L.P. raised its position in shares of Teva Pharmaceutical Industries Limited by 32.3% during the second quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock valued at $378,688,000 after buying an additional 2,782,257 shares during the last quarter. Institutional investors own 55.81% of the company’s stock.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at $11.74 on Tuesday. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. The firm has a market capitalization of $11,968.48, a PE ratio of 2.72 and a beta of 0.52. Teva Pharmaceutical Industries Limited has a fifty-two week low of $10.85 and a fifty-two week high of $41.19.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be issued a $0.085 dividend. The ex-dividend date is Monday, November 27th. This represents a $0.34 annualized dividend and a dividend yield of 2.90%. Teva Pharmaceutical Industries Limited’s payout ratio is currently -15.80%.

ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Holdings Reduced by Daiwa Securities Group Inc.” was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-holdings-reduced-by-daiwa-securities-group-inc/1702123.html.

Several research firms have recently issued reports on TEVA. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Sunday. J P Morgan Chase & Co cut shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to an “underweight” rating and reduced their price objective for the company from $11.48 to $11.00 in a research report on Monday. HSBC Holdings plc cut shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “reduce” rating in a research report on Tuesday, November 7th. Susquehanna Bancshares Inc reduced their price objective on shares of Teva Pharmaceutical Industries Limited from $20.00 to $14.00 and set a “positive” rating on the stock in a research report on Monday, November 6th. Finally, Credit Suisse Group reiterated an “underperform” rating and set a $8.00 price objective (down previously from $14.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, November 6th. Seven equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $22.26.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.